deltatrials
Completed NA INTERVENTIONAL 1-arm NCT00822107

A Translational Approach to Gitelman Syndrome

Sponsor: Oregon Clinical and Translational Research Institute

Interventions Hydrochlorothiazide
Updated 9 times since 2017 Last updated: Apr 1, 2019 Started: Jan 31, 2009 Primary completion: Jan 31, 2013 Completion: Sep 30, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00822107, this NA trial focuses on Gitelman Syndrome and remains completed. Sponsored by Oregon Clinical and Translational Research Institute, it has been updated 9 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~May 2019 · 11 months · monthly snapshotCompleted~May 2019 – ~Jan 2021 · 20 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

9 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2023 — Jul 2024 [monthly]

    Completed NA

  4. Dec 2022 — Jan 2023 [monthly]

    Completed NA

  5. Jan 2021 — Dec 2022 [monthly]

    Completed NA

Show 4 earlier versions
  1. May 2019 — Jan 2021 [monthly]

    Completed NA

  2. Jun 2018 — May 2019 [monthly]

    Completed NA

  3. Feb 2017 — Jun 2018 [monthly]

    Completed NA

  4. Jan 2017 — Feb 2017 [monthly]

    Completed NA

    First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Oregon Clinical and Translational Research Institute
  • Oregon Health and Science University
Data source: Oregon Health and Science University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations